Education
About Us
Working with TipRanks
Follow Us
Elicera Therapeutics AB (SE:ELIC)
:ELIC
Total Valuation
Elicera Therapeutics AB has a market cap or net worth of kr250.93M. The enterprise value is kr74.56M.
Market Capkr250.93M
Enterprise Valuekr74.56M
Share Statistics
Elicera Therapeutics AB has 48,535,545 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,535,545
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Elicera Therapeutics AB’s return on equity (ROE) is -0.78 and return on invested capital (ROIC) is -81.29%.
Return on Equity (ROE)-0.78
Return on Assets (ROA)-0.58
Return on Invested Capital (ROIC)-81.29%
Return on Capital Employed (ROCE)-0.81
Revenue Per Employee3.56M
Profits Per Employee-8.26M
Employee Count2
Asset Turnover0.26
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Elicera Therapeutics AB is -3.27. Elicera Therapeutics AB’s PEG ratio is -0.08.
PE Ratio-3.27
PS Ratio0.00
PB Ratio121.48
Price to Fair Value2.54
Price to FCF-311.92
Price to Operating Cash Flow-311.92
PEG Ratio-0.08
Income Statement
In the last 12 months, Elicera Therapeutics AB had revenue of 7.13M and earned -16.11M in profits. Earnings per share was -0.51.
Revenue7.13M
Gross Profit7.13M
Operating Income-16.88M
Pretax Income-16.11M
Net Income-16.11M
EBITDA-16.82M
Earnings Per Share (EPS)-0.51
Cash Flow
In the last 12 months, operating cash flow was -23.46M and capital expenditures 0.00, giving a free cash flow of -23.46M billion.
Operating Cash Flow-23.46M
Free Cash Flow-23.46M
Free Cash Flow per Share-0.48
Dividends & Yields
Elicera Therapeutics AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.82
52-Week Price Change296.17%
50-Day Moving Average4.65
200-Day Moving Average2.70
Relative Strength Index (RSI)52.17
Average Volume (3m)613.78K
Important Dates
Elicera Therapeutics AB upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.
Last Earnings DateApr 29, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend Date―
Financial Position
Elicera Therapeutics AB as a current ratio of 4.06, with Debt / Equity ratio of 0.00%
Current Ratio4.06
Quick Ratio4.06
Debt to Market Cap0.00
Net Debt to EBITDA1.57
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Elicera Therapeutics AB has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Elicera Therapeutics AB EV to EBITDA ratio is -1.56, with an EV/FCF ratio of -1.12.
EV to Sales3.69
EV to EBITDA-1.56
EV to Free Cash Flow-1.12
EV to Operating Cash Flow-1.12
Balance Sheet
Elicera Therapeutics AB has kr26.40M in cash and marketable securities with kr0.00 in debt, giving a net cash position of -kr26.40M billion.
Cash & Marketable Securitieskr26.40M
Total Debtkr0.00
Net Cash-kr26.40M
Net Cash Per Share-kr0.54
Tangible Book Value Per Sharekr0.66
Margins
Gross margin is 0.00%, with operating margin of -236.86%, and net profit margin of -226.01%.
Gross Margin0.00%
Operating Margin-236.86%
Pretax Margin-226.01%
Net Profit Margin-226.01%
EBITDA Margin-235.99%
EBIT Margin-236.16%
Analyst Forecast
The average price target for Elicera Therapeutics AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast31.92%